A consortium of investors led a $160m Series B funding round in Frontera Therapeutics.

Investment firms Boyu Capital, Sequoia China, OrbiMed and Creacion Ventures led a $160m Series B funding round in Frontera Therapeutics, a clinical-stage biotechnology company. “We are very pleased by the strong support from leading international investment firms in the completion of this financing round as we strive to create value for both patients and shareholders. The recent clearance of the IND for FT-001 by the FDA, which took less than 2 years to accomplish from program inception, is a testament to our execution capabilities," Yong Dai, Frontera Founder and CEO.